Edition:
United Kingdom

Luye Pharma Group Ltd (2186.HK)

2186.HK on Hong Kong Stock

5.91HKD
15 Oct 2018
Change (% chg)

HK$-0.09 (-1.50%)
Prev Close
HK$6.00
Open
HK$5.86
Day's High
HK$6.13
Day's Low
HK$5.86
Volume
9,532,290
Avg. Vol
19,749,094
52-wk High
HK$9.86
52-wk Low
HK$4.57

Chart for

About

Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and... (more)

Overall

Beta: --
Market Cap(Mil.): HK$15,675.47
Shares Outstanding(Mil.): 3,321.07
Dividend: --
Yield (%): --

Financials

  2186.HK Industry Sector
P/E (TTM): 15.59 30.89 32.75
EPS (TTM): 0.30 -- --
ROI: 13.25 15.08 14.60
ROE: 13.61 16.60 16.33

AstraZeneca sells rights for Seroquel to Luye Pharma for $538 million

LONDON British pharma company AstraZeneca said it had sold the rights for Seroquel, a treatment for schizophrenia and bipolar disease, to Luye Pharma Group for $538 million (396.8 million pounds), as part of a strategy to focus on other therapy areas.

08 May 2018

AstraZeneca sells rights for Seroquel to Luye Pharma for $538 million

LONDON British pharma company AstraZeneca said it had sold the rights for Seroquel, a treatment for schizophrenia and bipolar disease, to Luye Pharma Group for $538 million, as part of a strategy to focus on other therapy areas.

08 May 2018

AstraZeneca sells rights for Seroquel to Luye Pharma for $538 mln

LONDON, May 8 British pharma company AstraZeneca said it had sold the rights for Seroquel, a treatment for schizophrenia and bipolar disease, to Luye Pharma Group for $538 million, as part of a strategy to focus on other therapy areas.

08 May 2018

BRIEF-Luye Pharma Group Acquires Astrazeneca's Rights Relating To Seroquel And Seroquel XR

* ANNOUNCES ACQUISITION OF ASTRAZENECA'S RIGHTS RELATING TO SEROQUEL AND SEROQUEL XR IN CHINA AND IN OTHER TERRITORIES

07 May 2018

Earnings vs. Estimates